T2D and CV Risk Reduction: Future Management

June 12, 2019 12:51 pm

Future considerations for managing patients with type 2 diabetes and associated cardiovascular risk based on emerging data and clinical recommendations with SGLT2 inhibitors and GLP-1 agonists.

Category: News
About The Author
-
Previous

Hua Medicine – A Global Effort to Stop Diabetes
Next

EASD 2019 : Personalised Prevention Of CVD In T2D- Prof Alessandro Doria

Related Videos

Diabetologists-Perspective-of-Diabetes-and-Cardiovascular-Risk-Management-in-Post-ACS-T2D-patients

Diabetologist’s Perspective of Diabetes and Cardiovascular Risk Management in Post-ACS T2D patients

Type-2-diabetes-remission-Reducing-excess-fat-in-the-liver-might-be-the-keyteaser

Type 2 diabetes remission: Reducing excess fat in the liver might be the keyteaser

Team-based-care-for-patients-with-T2D-and-kidney-disease-Katherine-R-Tuttle-Jay-H-Shubrook

Team-based care for patients with T2D and kidney disease | Katherine R Tuttle & Jay H Shubrook

2038018

The Role of Nutrition in the Prevention and Intervention of Type 2 Diabetes

4-simple-tips-to-reverse-Type-2-Diabetes

4 simple tips to reverse Type 2 Diabetes

Rogelio-Braceras-MD-Improving-Costs-Comorbidities-in-T2D

Rogelio Braceras, MD: Improving Costs, Comorbidities in T2D